4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)

10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

DEFA14A - Nuvectis Pharma, Inc. (0001875558) (Filer)

DEF 14A - Nuvectis Pharma, Inc. (0001875558) (Filer)

10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executive Officer, will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious condit

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical activity warrants exploration of potential development opportunities in other cancer types NXP900 successfully completed a clinical drug-drug interaction (DDI) study in healthy volunteers and the Phase 1a dose escalation study; initiation of the NXP900 Phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents expected in the comi

Drug-drug interaction ("DDI") clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor ("EGFR") and anaplastic lymphoma kinase ("ALK") inhibitors for the treatment of non-small cell lung cancer ("NSCLC") are substrates of the Cytochrome P450 ("CYP") enzyme CYP3A, and therefore their combination with drugs that are strong inducers of CYP3A is to be avoided, or is contraindicated.As per the International Council for Harmonization ("ICH") M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor ConferenceDateMay 20th, 2025Time10:30 – 11:00 a.m. ETLinkNuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innova

Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2025 American Association for Cancer Research Meeting (2025 AACR), taking place from April 25th to April 30th in Chicago, IL. Presentation details are below: Abstract TitlePoster Presentation DetailsFirst in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumorsSession Title First-in-Hu

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch 17, 2025Time2:30 PM Pacific Time Linkhttps://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7 About Nuvectis Pharma Nuvectis Pharma, Inc. is a biopharmaceutical compa

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of